Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

2014 ◽  
Vol 143 (3) ◽  
pp. 579-586 ◽  
Author(s):  
Joanne Kotsopoulos ◽  
◽  
Jan Lubinski ◽  
Pal Moller ◽  
Henry T. Lynch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Brca1 Mutation ◽  
Oral Contraceptive Use ◽  
Mutation Carriers

scholarly journals Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Lieske H Schrijver ◽  
Håkan Olsson ◽  
Kelly-Anne Phillips ◽  
Mary Beth Terry ◽  
David E Goldgar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Cox Regression ◽  
Brca1 Mutation ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Full Cohort ◽  
Mutation Carriers ◽  
Prospective Analyses

Abstract Background For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. Methods Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. Results For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). Conclusions Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40–50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.

BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50

2006 ◽  
Vol 15 (10) ◽  
pp. 1863-1870 ◽  
Author(s):  
R. W. Haile ◽  
D. C. Thomas ◽  
V. McGuire ◽  
A. Felberg ◽  
E. M. John ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Oral Contraceptive Use ◽  
Mutation Carriers

scholarly journals The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users

2010 ◽  
Vol 63 (9-10) ◽  
pp. 657-661 ◽  
Author(s):  
Milena Veljkovic ◽  
Slavimir Veljkovic
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Young Women ◽  
Contraceptive Use ◽  
Epidemiologic Studies ◽  
Oral Contraceptive Use ◽  
Increased Risk

Introduction. Oral contraceptives, mainly combined monophasic pills, are widely used by young women who expect their physicians to prescribe them safe drugs which will not harm their health and which will simplify their life. Numerous epidemiologic studies have been performed to determine the relation between oral contraceptive use and the development of neoplasms. Breast cancer. An increased incidence of breast cancer has occurred simultaneously with the growing use of oral contraceptives. The possibility of a link between the oral contraceptive use and breast cancer has led to intensive research, but studies have provided inconsistent results causing confusion among clinicians. It was noticed that the risk of breast cancer was slightly elevated in current and recent young oral contraceptives users. That finding could be influenced by a detection bias or could be due to the biologic effect of the pills. The absolute number of additional breast cancer cases will be very small because of low baseline incidence of the disease in young women. Oral contraceptives probably promote growth of the already existing cancer, they are probably promoters not initiators of breast cancer. The available data do not provide a conclusive answer that is need. Cervical cancer. Numerous factors may influence the development of cervical cancer. The evidence suggests that current and recent oral contraceptive users have an increased risk of cervical cancer which decline after discontinuation of the application of medication. Oral contraceptives might increase the biological vulnerability of the cervix. Cervical cancer develops slowly over a long time period and can be effectively prevented by periodic cervical screening. Fortunately, oral contraceptives do not mask abnormal cervical citology. Conclusions regarding invasive cervical cancer and oral contraceptive use are not definitive but if there is any increased risk, it is low. Endometrial cancer. In oral contraceptive users the endometrium is almost under the influence of progestin component which suppresses endometrial mitotic activity and its proliferation. Most epidemiologic studies show that oral contraceptives reduce the risk of endometrial cancer and that this protective effect exists many years after the discontinuation of medication. Ovarian cancer. It has been long known that the oral contraceptive use causes protective an ovulation and reduces the risk of ovarian cancer. This powerful reduction is the best demonstrated major benefit of oral contraception. This protection is especially observed in nulliparous and seems to persist for many years after the discontinuation of medication.

Oral contraceptive use and risk of breast cancer in older women (New Zealand)

1995 ◽  
Vol 6 (6) ◽  
pp. 485-491 ◽  
Author(s):  
Charlotte Paul ◽  
David C. G. Skegg ◽  
George F. S. Spears
Keyword(s):  
Breast Cancer ◽  
New Zealand ◽  
Oral Contraceptive ◽  
Older Women ◽  
Contraceptive Use ◽  
Oral Contraceptive Use
Sign in / Sign up

Export Citation Format

Share Document